We evaluated the clinical effects of lamivudine treatment for hepatitis B virus carriers receiving chemotherapy and immunosuppressive therapy. Six cases were treated after HBV reactivation, and 3 cases were prophylactically treated from the beginning of immunosuppressive therapy. Except for a case with acute leukemia, who developed fibrosing cholestatic hepatitis, and died from pneumonia, sepsis and multiple organ failure without fatal hepatic failure, ALT of the other 5 cases, who were treated after HBV reactivation, became normal range within 6 months. Two cases had 106 copies HBV DNA in 1 mL of serum even after 6 months of therapy, indicating insufficiency of lamivudine. On the other hand, there was no HBV reactivation in three cases with prophylactic lamivudine treatment. Thus, we conclude that prophylactic lamivudine treatment is safer in managing HBV carriers receiving chemotherapy and immunosuppressive therapy than that after HBV replication.
|Number of pages||7|
|Journal||Japanese Pharmacology and Therapeutics|
|Publication status||Published - 2001|
- HBV carriers
- Immunosuppressive therapy
ASJC Scopus subject areas
- Pharmacology (medical)